Key result
DOACs for post-operative VTE prevention are linked to higher satisfaction and less difficulty than LMWH.
Why the study?
Extended VTE prophylaxis is recommended after laparotomy for gynecologic cancers, but patient satisfaction during a transition from LMWH to the DOAC apixaban had not been evaluated.
Does direct oral anticoagulant (apixaban) improve patient satisfaction compared to low molecular weight heparin for extended VTE prophylaxis in adult patients undergoing laparotomy for gynecologic malignancy?
Does direct oral anticoagulant (apixaban) improve patient satisfaction compared to low molecular weight heparin for extended VTE prophylaxis in adult patients undergoing laparotomy for gynecologic malignancy?
Answers are grounded in this paper and cite their sources.
DOACs (apixaban) provide significantly higher patient satisfaction, lower perceived costs, and less difficulty compared to LMWH for extended VTE prophylaxis after laparotomy for gynecologic cancer.
• Post-operative direct oral anticoagulant (DOAC) use following laparotomy is safe and effective for VTE prevention. • DOACs were highly acceptable to patients compared to low molecular weight heparin (LMWH) • Patients taking DOACs reported less difficulty, required less help, and lower costs compared to LMWH. Extended Venous Thromboembolism (VTE) prophylaxis is recommended for patients undergoing laparotomy for gynecologic cancers. The primary objective of this study was to evaluate patient satisfaction while our program transitioned from low molecular weight heparin (LMWH) to direct oral anticoagulant (DOAC) apixaban for extended VTE prophylaxis. Adult patients undergoing laparotomy for gynecologic malignancy in Alberta, Canada between April – December 2024 were considered for inclusion. The primary outcome was patient satisfaction, measured by the modified Anti-Clot Treatment Scale survey. Secondary outcomes included VTE incidence, major bleeding, and medication adherence. 111 patients were considered for inclusion; 50 patients completed the survey, and 40 patients had both survey and corresponding clinical data. All patients received pre-operative anticoagulation. Upon hospital discharge, 9 patients received LMWH, and 41 received DOAC. No patients experienced a VTE, and 1 patient on DOAC experienced a major bleed. Patients taking DOAC for extended VTE prophylaxis reported significantly less difficulty following anticoagulation treatment, less concern regarding cost of medication, and required less help compared to LMWH. The use of DOAC for extended VTE prophylaxis was associated with high patient satisfaction, further supporting its use in this context.
No takes yet. Share an insight, caveat, or question.
Black et al. (2026) studied this question. Post-operative direct oral anticoagulant use for VTE prevention in gynecologic cancer patients led to higher satisfaction and less difficulty compared to low molecular weight heparin.
Synapse has enriched 10 related papers. Consider them for comparative context: